10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0001576280-21-000080`
Period End Date	20210630
Filing Date	20210805
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	gh-20210630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 75 Income Statement 92 Cash Flow Statement 99 Stockholders Equity 48 Comprehensive Income 28

Balance Sheet 75 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$938.59M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$164.67M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$853.07M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$961.90M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$53.30M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$53.67M	USD	Point-in-time
Inventory	`InventoryNet`	$22.72M	USD	Point-in-time
Inventory	`InventoryNet`	$26.49M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$19.24M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$17.47M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	100.21M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.27M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.89B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.89B	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$246.60M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.27M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	100.21M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$55.37M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$62.78M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$89.74M	USD	Point-in-time
Assets	`Assets`	$2.29B	USD	Point-in-time
Assets	`Assets`	$2.27B	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$37.34M	USD	Point-in-time
Liabilities	`Liabilities`	$1.44B	USD	Point-in-time
Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$200.96M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$16.16M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$17.25M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$36.28M	USD	Point-in-time
Total Assets	`Assets`	$2.29B	USD	Point-in-time
Total Assets	`Assets`	$2.27B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.34M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$21.40M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$34.73M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$28.28M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$22.64M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$32.00M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$8.55M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$8.48M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$66.81M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$96.61M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$806.29M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$211.78M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$41.56M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.52M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.49M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.44B	USD	Point-in-time
Total Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$59.40M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$57.10M	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 101,265,100 and 100,213,985 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 101,265,100 and 100,213,985 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.90B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.60B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$2.70M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$33.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-606.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-809.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$847.05M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$788.07M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.11B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$785.11M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.29B	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.27B	USD	Point-in-time

Income Statement 92 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$50.99M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$72.60M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$136.33M	USD	2 Qtrs
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$111.24M	USD	2 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$34.43M	USD	2 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$22.61M	USD	2 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$15.34M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$19.50M	USD	1 Quarter
Total revenue	`Revenues`	$133.84M	USD	2 Qtrs
Total revenue	`Revenues`	$170.77M	USD	2 Qtrs
Total revenue	`Revenues`	$66.33M	USD	1 Quarter
Total revenue	`Revenues`	$92.10M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$17.81M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$24.89M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$48.48M	USD	2 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$36.00M	USD	2 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$5.04M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$4.63M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$10.20M	USD	2 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$6.94M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$119.23M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$73.33M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$36.32M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$63.72M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$25.02M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$82.05M	USD	2 Qtrs
Sales and marketing expense	`SellingAndMarketingExpense`	$47.72M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$50.13M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$116.31M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$48.38M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$56.97M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$37.19M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$120.95M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$189.74M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$223.38M	USD	2 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$376.27M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-205.50M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-54.62M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-97.64M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-89.53M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$2.59M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$2.64M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$5.96M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$1.04M	USD	1 Quarter
Interest expense	`InterestExpense`	$22.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$1.29M	USD	2 Qtrs
Interest expense	`InterestExpense`	$10.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$644.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.08M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-533.00K	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.29M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-243.00K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-97.49M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-81.52M	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-49.70M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-204.74M	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$83.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$48.00K	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$34.00K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$193.00K	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$2.30M	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$800.00K	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$4.90M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-82.37M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-54.64M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-97.58M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-207.23M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-54.64M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-97.58M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-207.23M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-82.37M	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-0.57	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-0.87	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-2.05	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-0.96	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-0.96	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-2.05	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-0.87	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-0.57	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.17M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.06M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	95.20M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	96.01M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.06M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	96.01M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	95.20M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.17M	shares	1 Quarter

Cash Flow Statement 99 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$7.11M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$10.64M	USD	2 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$10.84M	USD	2 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$3.39M	USD	2 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	2 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$875.00K	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-190.00K	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$32.15M	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$89.58M	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$1.28M	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	-	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.06M	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-6.53M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-8.00K	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$19.00K	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-6.89M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$368.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$3.78M	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$5.17M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-438.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.04M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$4.28M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$242.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-2.48M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$7.11M	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-31.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$6.46M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-1.82M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$7.30M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.88M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.03M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-70.00K	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-792.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-36.65M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-78.88M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$465.30M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$126.16M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$197.55M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$418.11M	USD	2 Qtrs
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFVNI`	-	USD	2 Qtrs
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFVNI`	$12.75M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$19.11M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$28.26M	USD	2 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	2 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-304.75M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$250.94M	USD	2 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$79.00K	USD	2 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$91.00K	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$5.39M	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$3.55M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$3.96M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$5.40M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$74.96M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	-	USD	2 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	-	USD	2 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$355.73M	USD	2 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$369.00K	USD	2 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	-	USD	2 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	2 Qtrs
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-65.04M	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$362.79M	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.00K	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-1.08M	USD	2 Qtrs
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$105.93M	USD	2 Qtrs
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$21.44M	USD	2 Qtrs
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$164.67M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$164.67M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$170.91M	USD	2 Qtrs
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$11.37M	USD	2 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$10.29M	USD	2 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$5.40M	USD	2 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	$587.00K	USD	2 Qtrs
Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses	`EquitySecuritiesFVNIIncurredButNotYetPaid`	-	USD	2 Qtrs
Follow-on public offering issuance costs included in accounts payable and accrued expenses	`OfferingCostsIncurredButNotYetPaid`	-	USD	2 Qtrs
Follow-on public offering issuance costs included in accounts payable and accrued expenses	`OfferingCostsIncurredButNotYetPaid`	$761.00K	USD	2 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$236.00K	USD	2 Qtrs
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	-	USD	2 Qtrs
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$938.59M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$164.67M	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	-	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$315.00K	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$164.67M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$938.90M	USD	Point-in-time

Stockholders Equity 48 line items

Line Item	Tag	Value	Unit	Period
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	2 Qtrs
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-800.00K	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-4.90M	USD	1 Quarter
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	4.31M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	2 Qtrs
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	1 Quarter
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	371,711.00	shares	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$926.00K	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.04M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.55M	USD	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.39M	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$26.00K	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$26.00K	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.40M	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.40M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$74.96M	USD	2 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$1.38M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$34.51M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$25.82M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$89.58M	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.15M	USD	2 Qtrs
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-2.66M	USD	2 Qtrs
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-871.00K	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-2.31M	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$4.28M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$788.07M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-97.58M	USD	1 Quarter
Net loss	`ProfitLoss`	$-204.93M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$4.23M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-878.00K	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-2.34M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.58M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$7.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$48.00K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.08M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$25.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-2.66M	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-871.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-2.31M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$4.28M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-77.29M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-98.45M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-207.60M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-52.05M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$800.00K	USD	2 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$2.30M	USD	2 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$4.90M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-56.95M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-209.90M	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-78.09M	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-98.45M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.